HONG KONG, May 23, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...
Phase 1b/2 combination study, FIRELIGHT-1, to leverage insights from pediatric development to evaluate potential synergistic effects of the two candidates...
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cashPrice per...
EMERYVILLE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the...
Quoin obtains option to exclusive global rights to product; no upfront or milestone feesASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE)...
The partnership will evaluate Lupagen’s extracorporeal in vivo delivery technology as a potential additional route of administration for Umoja’s VivoVec...
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
ROSELAND, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and...
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...
Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT CEO Mike O’Shea of...
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
- VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater...
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A....
Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee...
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of...
Independent safety review approved dose escalation and initiation of third and final dosing cohortSTAR-LLD well tolerated in all subjects dosed...
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and...
Fremont, CA, May 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing...